UK - Seraphim and Oxford further invest in Sirigen

Sirigen has developed a technology designed to enhance the sensitivity of tests and diagnostic assays by up to 100 fold, ussing novel light harvesting polymers to amplify signal. Biomedical companies use the company's product to optimise existing diagnostic assays and to develop the next generation of diagnostic tools, with the ultimate aim of personal healthcare management. Sirigen has recently entered into commercial agreements with three global diagnostic companies. The business, which was founded in 2003, is based in Hampshire and employs 15 staff.

The funding will be used to optimise the company's production strategies to deliver upon customer specific applications, each of which have market values in excess of $100m.

Seraphim and Oxford first supported Sirigen with a £2m investment in April 2008.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Expansion
• UK / Ireland
• Healthcare